Actavis Counting On Strong Product Line Depth For Avycaz Launch
Executive Summary
The specialty pharma will take advantage of its presence in antibiotics to launch its third FDA-approved antibiotic for hard-to-treat infections before the end of the second quarter.
You may also be interested in...
AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed
Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.
Targeted Antibiotics Could Get Limited Data Approval Option From FDA
Achaogen has designed a registration program with a single Phase III study for its next-generation aminoglycoside, plazomicin, to treat serious infections due to carbapenem-resistant Enterobacteriaceae, in what could be an interesting test for potential modifications to the standard approval pathway.
Forest Acquisition Of Cerexa Could Set The Stage For Ceftaroline Launch In 2010
The acquisition of the late-stage injectable antibiotic could launch ahead of Orapem.